PetMed Express received a non-binding acquisition proposal from SilverCape Investments for $4 per share, subject to conditions.
Quiver AI Summary
PetMed Express, Inc., also known as PetMeds, announced that it has received an unsolicited acquisition proposal from Singapore's SilverCape Investments Limited, offering to buy all outstanding shares for $4 each in cash. The proposal is non-binding and contingent on due diligence and a definitive agreement, without a financing contingency. Although PetMeds typically would not comment on such proposals, SilverCape disclosed its intentions publicly. The PetMeds Board of Directors will review the proposal in consultation with financial and legal advisors to ensure the decision aligns with the best interests of the company and its shareholders. The company advises stockholders not to take any action at this time, as the proposal is not a formal offer.
Potential Positives
- PetMed Express has received an unsolicited acquisition proposal offering $4 per share, indicating external interest in the company, which could lead to increased valuation and potential opportunities for stakeholders.
- The acquisition proposal is from SilverCape Investments Limited, a credible international investment firm, which enhances the perception of PetMeds as an attractive investment.
- The Board of Directors is engaging with financial and legal advisors to thoroughly review the proposal, demonstrating a commitment to fiduciary responsibility and the interests of stockholders.
- The company reaffirmed its position as a pioneer in the pet healthcare sector and highlighted its national licensing and expert staff, strengthening its brand reputation in the marketplace.
Potential Negatives
- The acquisition proposal priced at $4 per share may suggest a lack of confidence in the company's current valuation and could indicate that potential acquirers see limited growth prospects for PetMeds.
- The emphasis on the unsolicited and non-binding nature of the acquisition proposal may reflect internal uncertainties or issues that have prompted outside interest at a lower valuation than expected.
- Outstanding filings for the company's Quarterly Reports on Form 10-Q may raise concerns among investors regarding the company's financial transparency and compliance, affecting investor sentiment negatively.
FAQ
What acquisition proposal has PetMed Express received?
PetMed Express received an unsolicited acquisition proposal from SilverCape Investments to acquire all outstanding shares for $4 per share in cash.
Who is SilverCape Investments Limited?
SilverCape Investments Limited is a Singapore-based investment firm that has proposed to acquire PetMed Express, Inc.
What should PetMed shareholders do regarding the acquisition proposal?
PetMed shareholders do not need to take any action currently as the proposal is not a formal offer.
What is the role of PetMeds' Board of Directors in this proposal?
The Board will review SilverCape’s proposal in consultation with financial and legal advisors to determine the best course of action.
When was the acquisition proposal disclosed to the public?
The acquisition proposal from SilverCape was publicly disclosed on December 11, 2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PETS Insider Trading Activity
$PETS insiders have traded $PETS stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PETS stock by insiders over the last 6 months:
- INVESTMENTS LTD SILVERCAPE has made 6 purchases buying 271,977 shares for an estimated $867,483 and 0 sales.
- CAPITAL HOLDINGS INC. NINA purchased 25,000 shares for an estimated $87,425
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PETS Revenue
$PETS had revenues of $46.5M in Q4 2025. This is a decrease of -21.95% from the same period in the prior year.
You can track PETS financials on Quiver Quantitative's PETS stock page.
$PETS Hedge Fund Activity
We have seen 19 institutional investors add shares of $PETS stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVENOMIC CAPITAL MANAGEMENT LP removed 97,934 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $245,814
- BANK OF AMERICA CORP /DE/ removed 76,440 shares (-99.0%) from their portfolio in Q3 2025, for an estimated $191,864
- BLEAKLEY FINANCIAL GROUP, LLC removed 75,501 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $189,507
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 71,197 shares (-28.9%) from their portfolio in Q3 2025, for an estimated $178,704
- UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH removed 70,304 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $233,409
- JPMORGAN CHASE & CO removed 67,552 shares (-92.0%) from their portfolio in Q3 2025, for an estimated $169,555
- BRIDGEWAY CAPITAL MANAGEMENT, LLC added 67,016 shares (+164.3%) to their portfolio in Q3 2025, for an estimated $168,210
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DELRAY BEACH, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company” or “PetMeds”), today confirmed that it has received an unsolicited and non-binding acquisition proposal from SilverCape Investments Limited, a Singapore-based investment firm, to acquire all of the outstanding shares of the Company for $4 per share in cash, subject to various conditions such as due diligence and the execution of a mutually acceptable definitive agreement, but not subject to any financing contingency. While PetMeds would typically not publicly comment on privately submitted and non-binding acquisition proposals, SilverCape has publicly disclosed its proposal and the terms thereof in an amendment to its Schedule 13D that was filed with the U.S. Securities and Exchange Commission on December 11, 2025.
The PetMeds Board of Directors, consistent with its fiduciary duties and in consultation with its financial and legal advisors, will carefully review and consider SilverCape’s acquisition proposal to determine the course of action that it believes is in the best interests of PetMeds and its stockholders. PetMeds notes that SilverCape’s letter does not constitute a formal offer capable of acceptance and, as such, stockholders do not need to take any action at this time.
About PetMed Express, Inc.
Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the results of the now completed investigation by the Audit Committee of the Company’s Board of Directors, the risk that the completion of the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 may take longer than expected, and other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
Investor Contact
ICR, LLC
Reed Anderson
(646) 277-1260
[email protected]
